Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
使用先天免疫兴奋剂 PUL-042 扩大清髓性癌症治疗的市场和成功率
基本信息
- 批准号:9061821
- 负责人:
- 金额:$ 99.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-02-01 至 2018-04-30
- 项目状态:已结题
- 来源:
- 关键词:AchievementAddressAgonistAgreementAspergillus fumigatusAsthmaBacteriaBasic ScienceBiotechnologyBreathingCancer PatientClinicalClinical ResearchClinical TrialsCollaborationsCommunicable DiseasesCyclic GMPDataDevelopmentDoseDouble-blind trialEnrollmentEpitheliumEvaluationFundingGoalsHematologic NeoplasmsHematologyHumanImmuneImmune systemImmunityImmunocompromised HostIncidenceInfectionLeadLower Respiratory Tract InfectionLungMarketingMethodsMusMyeloablative ChemotherapyNasal Lavage FluidParainfluenzaPatientsPharmaceutical PreparationsPhasePhase II Clinical TrialsPlacebosPneumoniaPositioning AttributePreventionProcessPulmonologyRandomizedRecruitment ActivityResearchResistanceSafetySecureSeedsSendai virusSeveritiesSiteStagingSurvival RateTLR2 geneTechnologyTestingTherapeuticTimeToll-like receptorsTranslatingUnited States National Institutes of HealthUniversity of Texas M D Anderson Cancer CenterVaccinesViralVirusVirus Diseasesaerosolizedbasecancer therapyclinical research sitedesigndisease transmissionfollow-upfungushealthy volunteerimmune resistanceimmunosuppressedindividual patientinfluenzavirusmanmicrobialmicrobiomeneutralizing antibodynovel therapeuticsoncologyoutreachpandemic influenzapathogenphase I trialphase II trialpreventresistance mechanismrespiratoryresponsestudy populationsuccesstechnology developmentvirome
项目摘要
Pulmotect, Inc. was founded in 2007 to translate discoveries that induce innate immune resistance in the lung
into therapeutics that will provide protection from inhaled pathogens. Our technology platform is a direct result
of basic research by our founders on the mechanisms of microbial resistance in the lung epithelium. We have
developed an inhaled therapeutic, PUL-042, that provides immediate protection against a broad spectrum of
respiratory pathogens. PUL-042 is a clinical stage, specific combination of two well-characterized synthetic
molecules, a lipopeptide (Pam2CSK4) and an oligodeoxynucleotide (ODN M362) that act as agonists of the
Toll-like Receptors TLR2/6 and TLR9, respectively. This unique, proprietary combination of molecules
synergizes to rapidly and powerfully stimulate the body’s natural defenses. The response is localized and
specific to the site of administration. In mice, treatment before and after exposure with aerosolized PUL-042
results in increased survival rates to pathogens including multiple Gram+ and Gram– bacteria (three of which
are Class A bioterror agents), the fungus Aspergillus fumigatus, and the Sendai and influenza viruses. In each
case, increased survival is associated with a reduction of lung pathogen burden, not simply increased
tolerance to the pathogen by the host, which indicates a resistance mechanism of action.
Pulmotect's long-term strategy is to leverage its technology across a wide array of important threats from
inhaled pathogens by limiting the pathogen burden and transmission of disease. The range of applications for
PUL-042 currently in development includes use in immunosuppressed patients, pandemic influenza, asthma
exacerbations associated with viral infections and manmade bioterror threats as well as naturally emerging
viruses. While this broad spectrum technology is not envisioned to replace traditional vaccine approaches, its
value and differentiation reside in the ability to confer immediate host-based protection that is not limited by the
identity of the pathogen. The potential indications that lie outside the scope of this proposal are synergistic,
building on experimental methods that we established since our earliest research in this field. The scientific
basis of boosting the innate immune system in the lungs is rapidly expanding as we better understand the
underlying mechanism of action.
The primary goal of this proposal is to complete a Phase II clinical trial in immunosuppressed cancer patients.
This will be a multi-center randomized double-blind trial that will compare PUL-042 against placebo on the
overall incidence and severity of pneumonia, specifically on those who have been screened to have a
parainfluenza infection prior to enrollment. The three objectives of the trial are described below.
• Primary objective: to determine the safety and tolerability of PUL-042 inhalation solution in patients with
documented parainfluenza infection.
• Secondary objective: to determine the efficacy of PUL-042 inhalation solution to prevent the progression of
documented parainfluenza infection to clinically documented lower respiratory tract infection.
• Exploratory objectives: 1) evaluate the effect of PUL-042 on parainfluenza viral titers and neutralizing
antibodies; 2) evaluate the effect of PUL-042 over time on the microbiome and virome in nasal washes in
the study population; and 3) determine whether PUL-042 induces neutralizing antibodies against PUL-042
components.
The successful achievement of these objectives will demonstrate proof-of-concept in man and further validate
the technology for market use. With secured matching funds already in place, this NIH proposal is designed to
help move the project to the end goal, rather than provide the initial seed funds to start the process. The
Company would be well positioned to advance existing collaborations, partnerships and discussions with
leading large pharma and biotechnology organizations, accelerating the path to the market to address the
serious unmet needs that many patients are currently facing.
Pulmotect, Inc. 成立于 2007 年,致力于转化诱导肺部先天免疫抵抗的发现
进入可提供针对吸入病原体的保护的治疗方法。我们的技术平台是直接结果
我们的创始人对肺上皮微生物耐药机制的基础研究。我们有
开发了一种吸入疗法 PUL-042,可针对多种疾病提供立即保护
呼吸道病原体。 PUL-042是一种临床阶段的、两种特征良好的合成药物的特定组合
分子,脂肽(Pam2CSK4)和寡脱氧核苷酸(ODN M362)作为激动剂
Toll 样受体分别为 TLR2/6 和 TLR9。这种独特的、专有的分子组合
协同作用,快速有力地刺激身体的自然防御能力。响应是本地化的并且
具体到给药部位。在小鼠中,暴露于雾化 PUL-042 之前和之后的治疗
导致病原体的存活率提高,包括多种革兰氏+和革兰氏-细菌(其中三种
是 A 级生物恐怖制剂)、真菌烟曲霉、仙台病毒和流感病毒。在每个
在这种情况下,生存率的提高与肺部病原体负担的减少有关,而不仅仅是增加
宿主对病原体的耐受性,表明存在抵抗作用机制。
Pulmotect 的长期战略是利用其技术应对来自以下领域的各种重要威胁:
通过限制病原体负担和疾病传播来吸入病原体。应用范围
目前正在开发的 PUL-042 包括用于免疫抑制患者、大流行性流感、哮喘
与病毒感染和人为生物恐怖威胁以及自然出现的相关的恶化
病毒。虽然这种广谱技术预计不会取代传统的疫苗方法,但它
价值和差异化在于能够立即提供基于主机的保护,而不受
病原体的身份。本提案范围之外的潜在迹象具有协同作用,
建立在我们自该领域最早研究以来建立的实验方法的基础上。科学的
随着我们更好地了解,增强肺部先天免疫系统的基础正在迅速扩大
潜在的作用机制。
该提案的主要目标是在免疫抑制的癌症患者中完成 II 期临床试验。
这将是一项多中心随机双盲试验,将比较 PUL-042 与安慰剂的疗效
肺炎的总体发病率和严重程度,特别是那些经过筛查的人
入组前有副流感感染。该试验的三个目标如下所述。
• 主要目标:确定 PUL-042 吸入溶液在患有以下疾病的患者中的安全性和耐受性:
有记录的副流感感染。
• 次要目标:确定 PUL-042 吸入溶液预防病情进展的功效
记录的副流感感染到临床记录的下呼吸道感染。
• 探索性目标:1) 评估 PUL-042 对副流感病毒滴度和中和的影响
抗体; 2) 评估 PUL-042 随着时间的推移对鼻洗液中微生物组和病毒组的影响
研究人群; 3) 确定 PUL-042 是否诱导针对 PUL-042 的中和抗体
成分。
这些目标的成功实现将在人类中展示概念验证并进一步验证
市场使用的技术。随着有保障的配套资金已经到位,这项 NIH 提案旨在
帮助项目实现最终目标,而不是提供初始种子资金来启动该过程。这
公司将有能力推进现有的合作、伙伴关系和讨论
领先的大型制药和生物技术组织,加速进入市场的道路,以解决
许多患者目前面临着严重的未满足的需求。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brenton Scott其他文献
Brenton Scott的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brenton Scott', 18)}}的其他基金
Preventing asthma exacerbations by reducing viral respiratory infections
通过减少病毒性呼吸道感染来预防哮喘恶化
- 批准号:
8716580 - 财政年份:2012
- 资助金额:
$ 99.88万 - 项目类别:
Preventing asthma exacerbations by reducing viral respiratory infections
通过减少病毒性呼吸道感染来预防哮喘恶化
- 批准号:
8394355 - 财政年份:2012
- 资助金额:
$ 99.88万 - 项目类别:
Rapidly boosting innate immunity in the lungs to protect against pneumonia
快速增强肺部的先天免疫力以预防肺炎
- 批准号:
8604670 - 财政年份:2011
- 资助金额:
$ 99.88万 - 项目类别:
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
使用先天免疫兴奋剂 PUL-042 扩大清髓性癌症治疗的市场和成功率
- 批准号:
9265919 - 财政年份:2011
- 资助金额:
$ 99.88万 - 项目类别:
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
使用先天免疫兴奋剂 PUL-042 扩大清髓性癌症治疗的市场和成功率
- 批准号:
8875976 - 财政年份:2011
- 资助金额:
$ 99.88万 - 项目类别:
Rapidly boosting innate immunity in the lungs to protect against pneumonia
快速增强肺部的先天免疫力以预防肺炎
- 批准号:
8056839 - 财政年份:2011
- 资助金额:
$ 99.88万 - 项目类别:
Rapidly boosting innate immunity in the lungs to protect against pneumonia
快速增强肺部的先天免疫力以预防肺炎
- 批准号:
8455379 - 财政年份:2011
- 资助金额:
$ 99.88万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 99.88万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 99.88万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 99.88万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 99.88万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 99.88万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 99.88万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 99.88万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 99.88万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 99.88万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 99.88万 - 项目类别:
Research Grant